The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus will be on geographic atrophy, an advanced form of age-related macular degeneration that leads to irreversible vision loss.
Mizuho Maintains Buy on APA, Lowers Price Target to $52
Mizuho analyst Vincent Lovaglio maintains APA (NASDAQ:APA) with a Buy and lowers the price target from $54 to $52.
